Selected research
Market Analysis & Forecast
Global Aptamer CDMO Market Analysis and Forecast 2026-2032
Market perspective
The global Aptamer CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Aptamer CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Aptamer CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Aptamer CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Aptamer CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Aptamer CDMO include AMSBIO, Aptagen, Aptamer Group, PORTON, Base Pair, Base Pair Biotechnologies, Cambio, CD Bioparticles and Creative Biolabs, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Aptamer CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Aptamer CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Aptamer CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Aptamer CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Aptamer CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Aptamer CDMO revenue, projected growth trends, production technology, application and end-user industry.
Aptamer CDMO Segment by Company
AMSBIO
Aptagen
Aptamer Group
PORTON
Base Pair
Base Pair Biotechnologies
Cambio
CD Bioparticles
Creative Biolabs
Eurogentec
Novaptech
Aptamer CDMO Segment by Type
RNA Aptamer CDMO
DNA Aptamer CDMO
Others
Aptamer CDMO Segment by Application
Scientific Research
Medical Treatment
Others
Aptamer CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aptamer CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aptamer CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aptamer CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Aptamer CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Aptamer CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Aptamer CDMO revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Aptamer CDMO
- DNA Aptamer CDMO
- Others
Applications
- Scientific Research
- Medical Treatment
- Others
Companies covered
- AMSBIO
- Aptagen
- Aptamer Group
- PORTON
- Base Pair
- Base Pair Biotechnologies
- Cambio
- CD Bioparticles
- Creative Biolabs
- Eurogentec
- Novaptech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Aptamer CDMO Market by Type
- 1.2.1 Global Aptamer CDMO Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 RNA Aptamer CDMO
- 1.2.3 DNA Aptamer CDMO
- 1.2.4 Others
- 1.3 Aptamer CDMO Market by Application
- 1.3.1 Global Aptamer CDMO Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Scientific Research
- 1.3.3 Medical Treatment
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Aptamer CDMO Market Dynamics
- 2.1 Aptamer CDMO Industry Trends
- 2.2 Aptamer CDMO Industry Drivers
- 2.3 Aptamer CDMO Industry Opportunities and Challenges
- 2.4 Aptamer CDMO Industry Restraints
3 Global Growth Perspective
- 3.1 Global Aptamer CDMO Market Perspective (2021-2032)
- 3.2 Global Aptamer CDMO Growth Trends by Region
- 3.2.1 Global Aptamer CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Aptamer CDMO Market Size by Region (2021-2026)
- 3.2.3 Global Aptamer CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Aptamer CDMO Revenue by Players
- 4.1.1 Global Aptamer CDMO Revenue by Players (2021-2026)
- 4.1.2 Global Aptamer CDMO Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Aptamer CDMO Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Aptamer CDMO Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Aptamer CDMO Key Players Headquarters & Area Served
- 4.4 Global Aptamer CDMO Players, Product Type & Application
- 4.5 Global Aptamer CDMO Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Aptamer CDMO Market CR5 and HHI
- 4.6.3 2025 Aptamer CDMO Tier 1, Tier 2, and Tier 3
5 Aptamer CDMO Market Size by Type
- 5.1 Global Aptamer CDMO Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Aptamer CDMO Revenue by Type (2021-2032)
- 5.3 Global Aptamer CDMO Revenue Market Share by Type (2021-2032)
6 Aptamer CDMO Market Size by Application
- 6.1 Global Aptamer CDMO Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Aptamer CDMO Revenue by Application (2021-2032)
- 6.3 Global Aptamer CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 AMSBIO
- 7.1.1 AMSBIO Company Information
- 7.1.2 AMSBIO Business Overview
- 7.1.3 AMSBIO Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.1.4 AMSBIO Aptamer CDMO Product Portfolio
- 7.1.5 AMSBIO Recent Developments
- 7.2 Aptagen
- 7.2.1 Aptagen Company Information
- 7.2.2 Aptagen Business Overview
- 7.2.3 Aptagen Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.2.4 Aptagen Aptamer CDMO Product Portfolio
- 7.2.5 Aptagen Recent Developments
- 7.3 Aptamer Group
- 7.3.1 Aptamer Group Company Information
- 7.3.2 Aptamer Group Business Overview
- 7.3.3 Aptamer Group Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.3.4 Aptamer Group Aptamer CDMO Product Portfolio
- 7.3.5 Aptamer Group Recent Developments
- 7.4 PORTON
- 7.4.1 PORTON Company Information
- 7.4.2 PORTON Business Overview
- 7.4.3 PORTON Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.4.4 PORTON Aptamer CDMO Product Portfolio
- 7.4.5 PORTON Recent Developments
- 7.5 Base Pair
- 7.5.1 Base Pair Company Information
- 7.5.2 Base Pair Business Overview
- 7.5.3 Base Pair Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.5.4 Base Pair Aptamer CDMO Product Portfolio
- 7.5.5 Base Pair Recent Developments
- 7.6 Base Pair Biotechnologies
- 7.6.1 Base Pair Biotechnologies Company Information
- 7.6.2 Base Pair Biotechnologies Business Overview
- 7.6.3 Base Pair Biotechnologies Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.6.4 Base Pair Biotechnologies Aptamer CDMO Product Portfolio
- 7.6.5 Base Pair Biotechnologies Recent Developments
- 7.7 Cambio
- 7.7.1 Cambio Company Information
- 7.7.2 Cambio Business Overview
- 7.7.3 Cambio Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.7.4 Cambio Aptamer CDMO Product Portfolio
- 7.7.5 Cambio Recent Developments
- 7.8 CD Bioparticles
- 7.8.1 CD Bioparticles Company Information
- 7.8.2 CD Bioparticles Business Overview
- 7.8.3 CD Bioparticles Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.8.4 CD Bioparticles Aptamer CDMO Product Portfolio
- 7.8.5 CD Bioparticles Recent Developments
- 7.9 Creative Biolabs
- 7.9.1 Creative Biolabs Company Information
- 7.9.2 Creative Biolabs Business Overview
- 7.9.3 Creative Biolabs Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.9.4 Creative Biolabs Aptamer CDMO Product Portfolio
- 7.9.5 Creative Biolabs Recent Developments
- 7.10 Eurogentec
- 7.10.1 Eurogentec Company Information
- 7.10.2 Eurogentec Business Overview
- 7.10.3 Eurogentec Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.10.4 Eurogentec Aptamer CDMO Product Portfolio
- 7.10.5 Eurogentec Recent Developments
- 7.11 Novaptech
- 7.11.1 Novaptech Company Information
- 7.11.2 Novaptech Business Overview
- 7.11.3 Novaptech Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 7.11.4 Novaptech Aptamer CDMO Product Portfolio
- 7.11.5 Novaptech Recent Developments
8 North America
- 8.1 North America Aptamer CDMO Revenue (2021-2032)
- 8.2 North America Aptamer CDMO Revenue by Type (2021-2032)
- 8.2.1 North America Aptamer CDMO Revenue by Type (2021-2026)
- 8.2.2 North America Aptamer CDMO Revenue by Type (2027-2032)
- 8.3 North America Aptamer CDMO Revenue Share by Type (2021-2032)
- 8.4 North America Aptamer CDMO Revenue by Application (2021-2032)
- 8.4.1 North America Aptamer CDMO Revenue by Application (2021-2026)
- 8.4.2 North America Aptamer CDMO Revenue by Application (2027-2032)
- 8.5 North America Aptamer CDMO Revenue Share by Application (2021-2032)
- 8.6 North America Aptamer CDMO Revenue by Country
- 8.6.1 North America Aptamer CDMO Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Aptamer CDMO Revenue by Country (2021-2026)
- 8.6.3 North America Aptamer CDMO Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Aptamer CDMO Revenue (2021-2032)
- 9.2 Europe Aptamer CDMO Revenue by Type (2021-2032)
- 9.2.1 Europe Aptamer CDMO Revenue by Type (2021-2026)
- 9.2.2 Europe Aptamer CDMO Revenue by Type (2027-2032)
- 9.3 Europe Aptamer CDMO Revenue Share by Type (2021-2032)
- 9.4 Europe Aptamer CDMO Revenue by Application (2021-2032)
- 9.4.1 Europe Aptamer CDMO Revenue by Application (2021-2026)
- 9.4.2 Europe Aptamer CDMO Revenue by Application (2027-2032)
- 9.5 Europe Aptamer CDMO Revenue Share by Application (2021-2032)
- 9.6 Europe Aptamer CDMO Revenue by Country
- 9.6.1 Europe Aptamer CDMO Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Aptamer CDMO Revenue by Country (2021-2026)
- 9.6.3 Europe Aptamer CDMO Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Aptamer CDMO Revenue (2021-2032)
- 10.2 China Aptamer CDMO Revenue by Type (2021-2032)
- 10.2.1 China Aptamer CDMO Revenue by Type (2021-2026)
- 10.2.2 China Aptamer CDMO Revenue by Type (2027-2032)
- 10.3 China Aptamer CDMO Revenue Share by Type (2021-2032)
- 10.4 China Aptamer CDMO Revenue by Application (2021-2032)
- 10.4.1 China Aptamer CDMO Revenue by Application (2021-2026)
- 10.4.2 China Aptamer CDMO Revenue by Application (2027-2032)
- 10.5 China Aptamer CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Aptamer CDMO Revenue (2021-2032)
- 11.2 Asia Aptamer CDMO Revenue by Type (2021-2032)
- 11.2.1 Asia Aptamer CDMO Revenue by Type (2021-2026)
- 11.2.2 Asia Aptamer CDMO Revenue by Type (2027-2032)
- 11.3 Asia Aptamer CDMO Revenue Share by Type (2021-2032)
- 11.4 Asia Aptamer CDMO Revenue by Application (2021-2032)
- 11.4.1 Asia Aptamer CDMO Revenue by Application (2021-2026)
- 11.4.2 Asia Aptamer CDMO Revenue by Application (2027-2032)
- 11.5 Asia Aptamer CDMO Revenue Share by Application (2021-2032)
- 11.6 Asia Aptamer CDMO Revenue by Country
- 11.6.1 Asia Aptamer CDMO Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Aptamer CDMO Revenue by Country (2021-2026)
- 11.6.3 Asia Aptamer CDMO Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Aptamer CDMO Revenue (2021-2032)
- 12.2 SAMEA Aptamer CDMO Revenue by Type (2021-2032)
- 12.2.1 SAMEA Aptamer CDMO Revenue by Type (2021-2026)
- 12.2.2 SAMEA Aptamer CDMO Revenue by Type (2027-2032)
- 12.3 SAMEA Aptamer CDMO Revenue Share by Type (2021-2032)
- 12.4 SAMEA Aptamer CDMO Revenue by Application (2021-2032)
- 12.4.1 SAMEA Aptamer CDMO Revenue by Application (2021-2026)
- 12.4.2 SAMEA Aptamer CDMO Revenue by Application (2027-2032)
- 12.5 SAMEA Aptamer CDMO Revenue Share by Application (2021-2032)
- 12.6 SAMEA Aptamer CDMO Revenue by Country
- 12.6.1 SAMEA Aptamer CDMO Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Aptamer CDMO Revenue by Country (2021-2026)
- 12.6.3 SAMEA Aptamer CDMO Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst